Although the trial did not show a significant advantage in reducing cardiovascular events [6], or hospitalizations, it provided insights into liraglutides safety and tolerability in this patient population [6]
Contact TruLaw using the chat on this page to receive an instant case evaluation and learn if you qualify to join others filing Ozempic lawsuits today
Also, high treatment costs, supply constraints, and increasing competition from new obesity and diabetes therapies hinder the market
It was the first paper to show the therapeutic potential of GLP-1 (7-37) for treatment of type 2 diabetes (Nathan, Schreiber, Fogel
Human genetics of metabolic dysfunction-associated steatotic liver disease: from variants to cause to precision treatment
Many users reported experiencing sulfur burps after Ozempic introduction to their regimen